zeprumetostat + chidamide

The combination of zeprumetostat and chidamide is an investigational epigenetic therapy being evaluated for the treatment of hematological malignancies, particularly peripheral T-cell lymphoma (PTCL). Zeprumetostat (SHR2554) is an oral, selective, small molecule inhibitor of Enhancer of Zeste Homolog 2 (EZH2), a histone methyltransferase that often promotes tumor growth through gene silencing. Chidamide is a benzamide-type, subtype-selective histone deacetylase (HDAC) inhibitor that targets HDAC 1, 2, 3, and 10. Preclinical research has demonstrated synergistic anti-tumor activity between these two agents, as they simultaneously modulate different epigenetic pathways to reverse transcriptional repression and induce apoptosis in lymphoma cells. This combination is currently being studied in a genotype-guided Phase 1/2 clinical trial sponsored by Ruijin Hospital for patients with primary refractory PTCL.

Other names

SHR2554 + chidamidezeprumetostat + chidamide-Ruijin Hospital-peripheral T-cell lymphoma